Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 77NETWORK 21NIH 15OTHER_GOV 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 47Head & Neck 28Thoracic 26Gastrointestinal 20Genitourinary 10Breast 8Lymphoid 6Sarcoma 5Other 5Tumor-Agnostic 3Other solid neoplasm 2Other hematologic neoplasm 2Plasma cell 1Myeloid 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Uterine Cervical Neoplasms 1Camurati-Engelmann Syndrome 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Radiotherapy × Gynecologic × Clear all
NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

EMD Serono

Phase 1 Completed
25 enrolled 14 charts
Gynecologic

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡